Log In
BCIQ
Print this Print this
 

MTR106

  Manage Alerts
Collapse Summary General Information
Company Meditor Pharmaceuticals Ltd.
DescriptionImmediate-release oral tablet formulation of MTR104, a low molecular weight S-Alkylisothiouronium derivative
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationMigraine
Indication DetailsTreat acute migraine without aura in women
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today